期刊
CLINICAL INFECTIOUS DISEASES
卷 62, 期 2, 页码 258-261出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/civ841
关键词
immune reconstitution inflammatory syndrome; infliximab; mycobacterial infection
资金
- NCI NIH HHS [HHSN261200800001E] Funding Source: Medline
- PHS HHS [261200800001E] Funding Source: Medline
- CCR NIH HHS [HHSN261200800001C] Funding Source: Medline
The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据